Dance Biopharm focuses on developing soft mist inhalable formulations of biologics and a connected, handheld delivery device. Its lead product, Dance 501, is a preservative-free inhaled recombinant human insulin delivered via a proprietary soft mist device designed for high lung deposition. The company is preparing to initiate a global Phase 3 program for Dance 501 in patients with type 1 and type 2 diabetes in mid-2020. Dance is also advancing Dance 601, a GLP-1 analog, toward IND-enabling studies. The company was founded in 2010 and is based in the San Francisco Bay Area. Proceeds from recent financing will fund manufacturing for Phase 3 studies, IND-enabling studies, organizational preparation, and general corporate purposes. Dance Biopharm Inc. is a Brisbane, CA–based biotechnology company focused on developing inhaled insulin products to treat diabetes. Led by chairman and CEO Dr. John Patton, the company began operations in 2010 and is advancing Dance 501, an inhaled insulin product consisting of a high-purity liquid formulation of recombinant human insulin. Dance 501 is stored in a dispenser for administration with a small handheld electronic inhaler that uses patented vibrating mesh technology to produce consistently sized particles as a smooth mist. The design is intended to deliver insulin into the lungs in a few breaths. The company completed a $9.5m financing (convertible notes and warrants) to fund human clinical studies, manufacture drug and devices for clinical studies, and for working capital and general corporate purposes. Participants were a syndicate of individual and institutional investors, the majority focused on the biotechnology and healthcare sectors.

Total raised

$30M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2019